Arformoterol Nebulizer Solution
Pharmacy prior authorization / step-edit request form and clinical criteria for coverage of arformoterol nebulizer solution (Brovana) including required prescriber/member information, dosing recommendation, and step therapy failure requirement.
No material clinical or coverage changes
Coverage Summary
This document is a pharmacy prior authorization / step-edit request form and the clinical criteria for coverage of arformoterol nebulizer solution (Brovana). It requires completed member and prescriber information (including prescriber signature and contact details), drug information (form/strength, dosing schedule, length of therapy, diagnosis, ICD code if applicable, weight, date), and documentation supporting the clinical criteria for approval.
The dosing recommendation specified is 15 mcg twice daily; maximum: 30 mcg/day. Approval requires meeting all listed clinical criteria and submission of supporting documentation (e.g., pharmacy paid claims or chart notes).
A required step-therapy requirement is documented: the member must have had an unsuccessful 30-day trial of Serevent Diskus 50 mcg/dose inhaler (verification via pharmacy paid claims or chart notes).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.